GenFleet’s GFH276 enters Phase Ib/II combination study
AI Summary- GenFleet Therapeutics advanced GFH276 into a Phase Ib/II combination therapy study.
- GFH276 is an oral pan-RAS inhibitor being tested across multiple centers.
- The first overseas patient was dosed in Australia, while China’s first patient was dosed in the third.